Aarti Pharmalabs Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Aarti Pharmalabs Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹817

Market cap₹6.2K Cr

P/E35.0

Published13 Jun 2026

The short version

The company targets a long-term revenue growth of 15% to 18% annually over the next 3-4 years. Revenue growth guidance of 15%-18% CAGR over the next 3-4 years.

From Aarti Pharmalabs Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

The company targets a long-term revenue growth of 15% to 18% annually over the next 3-4 years.
CDMO vertical is expected to grow at a robust 40%-50% next year (FY2027), driving higher value growth.
Xanthine segment aims to achieve around Rs.1,000 Crores revenue in FY2027, showing strong volume and value growth.
API/intermediates segment is expected to surpass FY2025 revenue levels (approx. Rs.700-770 Crores) in FY2027, recovering from previous degrowth due to inventory and price erosion issues.
Ramp-up of new capacities (Atali and Xanthine expansion) to contribute meaningfully to revenues and EBITDA starting from FY2027 Q2 onwards.
Working capital needs may increase due to upfront inventory buildup for large customer projects with no advance payments.
Revenue adjustments due to foreign exchange fluctuations are expected but overall growth trajectory remains positive.

Profitability & Margins

Revenue growth guidance of 15%-18% CAGR over the next 3-4 years.
EBITDA margin guidance maintained at 15%-18% over the same period.
EBITDA growth expected to materialize meaningfully from Q1 FY2027 onwards as recent capex ramps up, with full contribution taking about a year.
CDMO segment expected to grow 40%-50% in FY2027, driving higher revenue.
Xanthine segment anticipated to reach Rs.1000 Crores revenue in FY2027, surpassing FY2025 levels.
API/intermediates segment expected to recover and surpass FY2025 revenue levels (~Rs.700 Crores).
Capex intensity to reduce from FY2028 as major greenfield projects complete; future expansions to be brownfield, enabling faster ramp-up and better capital efficiency.
EPS growth aligned with revenue and margin expansion, though exact figures not explicitly provided.
Foreign exchange losses excluded from EBITDA guidance.

See what Aarti Pharmalabs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Rs.400 Crores capex planned for FY2027, spread across four primary areas: completion of Xanthine expansion, Atali Phase 1 capitalization and start of Phase 2, debottlenecking projects, and normal replacement capex.
Capex for dedicated manufacturing block is included but the exact amount is still being finalized.
Atali plant expansion to continue with one new block per year, focusing more on brownfield expansions going forward to reduce capex intensity and speed up ramp-up.
Xanthine derivative capacity to increase from 6,000 to 9,000 metric tons per annum by gradual ramp-up next few quarters.
Steroid and anticancer blocks at Tarapur Unit-4 are undergoing debottlenecking and brownfield expansions in FY2027.
Preliminary design and planning of a dedicated manufacturing block tailored to specific projects; completion expected approximately 12 months after construction begins.
Investment in R&D for peptides and oligonucleotides with long-term potential but no immediate results expected.

Fundraising & Capital Structure

There is no specific mention of any current fundraising through debt or equity in the transcript.
The company has term loans which lead to foreign currency losses, but no new debt fundraising is mentioned.
Capex for dedicated blocks and expansions is being self-funded primarily through cash flows from operations, especially the Xanthine business.
The company is undertaking significant capex (~Rs.400 Crores planned for the current year) mainly from internal accruals rather than raising new external funds.
Future capex is expected to be more brownfield with lower intensity and the balance sheet strength is emphasized as a factor helping in CDMO partnerships.
Rashesh Gogri indicated capex decisions are backed by customer commitments and forward-looking project visibility, suggesting controlled and funded expansion rather than raising fresh capital.

See what Aarti Pharmalabs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The company currently has 21 active CDMO customers, a number steady over the last five quarters.
Engagements with these customers are ongoing for newer projects, indicating pipeline development.
In 2025, there was a slowdown in inquiries due to global uncertainties, but the situation has stabilized with increasing inquiries now.
The management mentions having long-term and near-term understandings with customers regarding volumes for new capacities, indicating good visibility on future orders.
Capex decisions for custom-built facilities are based on sensible forecasts from customers.
Large projects tend to have one or two deliveries per year, leading to inventory buildup before delivery.
Customers do not typically provide advance payments, so inventory financing is done by the company.
Overall, the inquiry pipeline is improving compared to the slowdown in the prior year.

How does Aarti Pharmalabs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAarti Pharmalabs Ltd

See where Aarti Pharmalabs Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

Aarti Pharmalabs Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹583 Cr, net profit ₹61 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Aarti Pharmalabs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
Sai Parenteral's (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…

Compare:vs Sun Pharmaceutical Industries Ltd vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Aarti Pharmalabs Ltd Q4 FY26 results?

The company targets a long-term revenue growth of 15% to 18% annually over the next 3-4 years. Revenue growth guidance of 15%-18% CAGR over the next 3-4 years.

What is Aarti Pharmalabs Ltd share price analysis?

Aarti Pharmalabs Ltd currently shows a neutral. The stock trades at a P/E of 35.0 with a market cap of ₹6,193 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aarti Pharmalabs Ltd planning capital expenditure?

Rs.400 Crores capex planned for FY2027, spread across four primary areas: completion of Xanthine expansion, Atali Phase 1 capitalization and start of Phase 2, debottlenecking projects, and normal replacement capex.

Keep Aarti Pharmalabs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.